Prucalopride, Motegrity’s bioequivalent, treats chronic idiopathic constipation in adults. Motegrity’s 2025 U.S. sales reached $184M. Lupin, a global pharma leader, develops complex generics and APIs.

• Prucalopride treats chronic idiopathic constipation, a bioequivalent to Motegrity, with 2025 U.S. sales of $184M.
• Lupin, a Mumbai-based pharma leader, specializes in complex generics, biotech products, and APIs for 100+ markets.
• Prucalopride’s launch as a Motegrity alternative offers cost-effective treatment for CIC, enhancing market accessibility.